These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22001870)

  • 1. Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.
    Verreault M; Strutt D; Masin D; Anantha M; Waterhouse D; Yapp DT; Bally MB
    J Control Release; 2012 Feb; 158(1):34-43. PubMed ID: 22001870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
    Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
    J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
    J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
    Verreault M; Strutt D; Masin D; Anantha M; Yung A; Kozlowski P; Waterhouse D; Bally MB; Yapp DT
    BMC Cancer; 2011 Apr; 11():124. PubMed ID: 21477311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.
    Hare JI; Neijzen RW; Anantha M; Dos Santos N; Harasym N; Webb MS; Allen TM; Bally MB; Waterhouse DN
    PLoS One; 2013; 8(4):e62349. PubMed ID: 23626804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
    Waterhouse DN; Sutherland BW; Santos ND; Masin D; Osooly M; Strutt D; Ostlund C; Anantha M; Harasym N; Manisali I; Wehbe M; Bally MB; Webb MS
    Invest New Drugs; 2014 Dec; 32(6):1071-82. PubMed ID: 25064374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.
    Ramsay EC; Anantha M; Zastre J; Meijs M; Zonderhuis J; Strutt D; Webb MS; Waterhouse D; Bally MB
    Clin Cancer Res; 2008 Feb; 14(4):1208-17. PubMed ID: 18281556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
    Ma MK; Zamboni WC; Radomski KM; Furman WL; Santana VM; Houghton PJ; Hanna SK; Smith AK; Stewart CF
    Clin Cancer Res; 2000 Mar; 6(3):813-9. PubMed ID: 10741701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations.
    Ahmad N; Alam MA; Ahmad R; Umar S; Jalees Ahmad F
    J Microencapsul; 2018 Jun; 35(4):327-343. PubMed ID: 29873288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.
    Noble CO; Krauze MT; Drummond DC; Forsayeth J; Hayes ME; Beyer J; Hadaczek P; Berger MS; Kirpotin DB; Bankiewicz KS; Park JW
    Nanomedicine (Lond); 2014 Jul; 9(14):2099-108. PubMed ID: 24494810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.
    Chen PY; Ozawa T; Drummond DC; Kalra A; Fitzgerald JB; Kirpotin DB; Wei KC; Butowski N; Prados MD; Berger MS; Forsayeth JR; Bankiewicz K; James CD
    Neuro Oncol; 2013 Feb; 15(2):189-97. PubMed ID: 23262509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
    Goldwirt L; Beccaria K; Carpentier A; Idbaih A; Schmitt C; Levasseur C; Labussiere M; Milane A; Farinotti R; Fernandez C
    J Neurooncol; 2015 Apr; 122(2):273-81. PubMed ID: 25794638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
    Messerer CL; Ramsay EC; Waterhouse D; Ng R; Simms EM; Harasym N; Tardi P; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Oct; 10(19):6638-49. PubMed ID: 15475454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
    Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
    Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
    Riviere K; Kieler-Ferguson HM; Jerger K; Szoka FC
    J Control Release; 2011 Aug; 153(3):288-96. PubMed ID: 21600250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
    Adkins CE; Nounou MI; Hye T; Mohammad AS; Terrell-Hall T; Mohan NK; Eldon MA; Hoch U; Lockman PR
    BMC Cancer; 2015 Oct; 15():685. PubMed ID: 26463521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.
    Stewart CF; Zamboni WC; Crom WR; Houghton PJ
    Cancer Chemother Pharmacol; 1997; 40(3):259-65. PubMed ID: 9219511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
    Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
    J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
    Zamboni WC; Houghton PJ; Thompson J; Cheshire PJ; Hanna SK; Richmond LB; Lou X; Stewart CF
    Clin Cancer Res; 1998 Feb; 4(2):455-62. PubMed ID: 9516936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
    Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
    Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.